Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Structure, chemistry, and pharmacokinetics of intravenous iron agents.

Literature DB >> 15585603

Structure, chemistry, and pharmacokinetics of intravenous iron agents.

Bo G Danielson¹.

Abstract

Entities: Chemical

Mesh：

Substances：
Colloids
Iron

Year: 2004 PMID： 15585603 DOI： 10.1097/01.ASN.0000143814.49713.C5

Source DB: PubMed Journal: J Am Soc Nephrol ISSN： 1046-6673 Impact factor: 10.121

Keyword Cloud
Cited

× No keyword cloud information.

58 in total

Review 1. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.

Authors: Manuel Muñoz; José Antonio García-Erce; Jorge Cuenca; Elvira Bisbe; Enrique Naveira
Journal: Blood Transfus Date: 2011-11-30 Impact factor: 3.443

2. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.

Authors: Ali C M Johnson; Kirsten Becker; Richard A Zager
Journal: Am J Physiol Renal Physiol Date: 2010-05-26

3. Iron-deficiency anaemia in the Emergency Room: a new opportunity for the use of intravenous iron.

Authors: Dan Morhaim; Michael Auerbach
Journal: Blood Transfus Date: 2015-11-19 Impact factor: 3.443

4. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer^® ) versus ferric carboxy-maltose (Ferinject^® ). A single center, cohort study.

Authors: Midas B Mulder; Hester L van den Hoek; Erwin Birnie; Antonie J P van Tilburg; Elsbeth M Westerman
Journal: Br J Clin Pharmacol Date: 2018-12-11 Impact factor: 4.335

Structure, chemistry, and pharmacokinetics of intravenous iron agents.

Review 1. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.

2. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.

3. Iron-deficiency anaemia in the Emergency Room: a new opportunity for the use of intravenous iron.

4. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer^® ) versus ferric carboxy-maltose (Ferinject^® ). A single center, cohort study.

Review 5. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

6. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics.

7. Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?

Review 8. Considerations and challenges in defining optimal iron utilization in hemodialysis.

Review 9. Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

10. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Structure, chemistry, and pharmacokinetics of intravenous iron agents.

Review 1. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.

2. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.

3. Iron-deficiency anaemia in the Emergency Room: a new opportunity for the use of intravenous iron.

4. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study.

Review 5. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

6. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics.

7. Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?

Review 8. Considerations and challenges in defining optimal iron utilization in hemodialysis.

Review 9. Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

10. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

4. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer^® ) versus ferric carboxy-maltose (Ferinject^® ). A single center, cohort study.